Comparative Pharmacology
Head-to-head clinical analysis: ACTICLATE CAP versus ARESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICLATE CAP versus ARESTIN.
ACTICLATE CAP vs ARESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding.
Minocycline is a semisynthetic tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the elongating peptide chain. This action is bacteriostatic. In periodontal disease, it also inhibits matrix metalloproteinases (MMPs), particularly collagenase, and suppresses inflammatory cytokine production, reducing tissue destruction.
350 mg orally once daily, increased to 350 mg twice daily if no response after 2 weeks.
1 mg subgingival application per periodontal pocket, applied as a single dose by a dental professional.
None Documented
None Documented
Terminal elimination half-life 6-10 hours; prolonged in renal impairment (up to 22 hours in anuria)
The terminal elimination half-life of minocycline is 11-17 hours (mean ~16 hours). This long half-life allows for twice-daily dosing in systemic use, but for Arestin (subgingival), local sustained release provides prolonged local exposure.
Renal (60-70% as unchanged drug), fecal (20-30% as metabolites); minor biliary elimination
Minocycline is primarily eliminated via hepatic metabolism and biliary/fecal excretion. Renal excretion accounts for approximately 10-20% of the dose, with the remainder excreted in feces via bile. Less than 10% is recovered unchanged in urine.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic